Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

J. Nam; E. Villeneuve; E.M.A. Hensor; P.G. Conaghan; Helen Keen; M.H. Buch; A.K.S. Gough; M.J. Green; P.S. Helliwell; A.M. Keenan; A.W. Morgan; M.A. Quinn; R.J. Reece; D.M.F.M. Van Der Heijde; R.J. Wakefield; P.D. Emery

doi:10.1136/annrheumdis-2013-203440

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

J. Nam, E. Villeneuve, E.M.A. Hensor, P.G. Conaghan, Helen Keen, M.H. Buch, A.K.S. Gough, M.J. Green, P.S. Helliwell, A.M. Keenan, A.W. Morgan, M.A. Quinn, R.J. Reece, D.M.F.M. Van Der Heijde, R.J. Wakefield, P.D. Emery

Research output: Contribution to journal › Article › peer-review

135 Citations (Scopus)

Abstract

Objectives In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX and intravenous corticosteroid for remission induction. Methods In a 78-week multicentre randomised controlled trial, double-blinded to week 26, 112 treatment-naive RA patients (1987 American College of Rheumatology classification criteria) with disease activity score 44 (DAS44)>2.4 were randomised to MTX + IFX or MTX + single dose intravenous methylprednisolone 250 mg. A treat-to-target approach was used with treatment escalation if DAS44>2.4. In the IFX group, IFX was discontinued for sustained remission (DAS44

Original language	English
Pages (from-to)	75-85
Journal	Annals of the Rheumatic Diseases
Volume	73
Issue number	1
DOIs	https://doi.org/10.1136/annrheumdis-2013-203440
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/annrheumdis-2013-203440

Fingerprint

Dive into the research topics of 'Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)'. Together they form a unique fingerprint.

Cite this

Nam, J., Villeneuve, E., Hensor, E. M. A., Conaghan, P. G., Keen, H., Buch, M. H., Gough, A. K. S., Green, M. J., Helliwell, P. S., Keenan, A. M., Morgan, A. W., Quinn, M. A., Reece, R. J., Van Der Heijde, D. M. F. M., Wakefield, R. J., & Emery, P. D. (2014). Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Annals of the Rheumatic Diseases, 73(1), 75-85. https://doi.org/10.1136/annrheumdis-2013-203440

@article{0e85fc1712e74ec0affb885aa367cd11,

title = "Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)",

abstract = "Objectives In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX and intravenous corticosteroid for remission induction. Methods In a 78-week multicentre randomised controlled trial, double-blinded to week 26, 112 treatment-naive RA patients (1987 American College of Rheumatology classification criteria) with disease activity score 44 (DAS44)>2.4 were randomised to MTX + IFX or MTX + single dose intravenous methylprednisolone 250 mg. A treat-to-target approach was used with treatment escalation if DAS44>2.4. In the IFX group, IFX was discontinued for sustained remission (DAS44",

author = "J. Nam and E. Villeneuve and E.M.A. Hensor and P.G. Conaghan and Helen Keen and M.H. Buch and A.K.S. Gough and M.J. Green and P.S. Helliwell and A.M. Keenan and A.W. Morgan and M.A. Quinn and R.J. Reece and {Van Der Heijde}, D.M.F.M. and R.J. Wakefield and P.D. Emery",

year = "2014",

doi = "10.1136/annrheumdis-2013-203440",

language = "English",

volume = "73",

pages = "75--85",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Publishing Group",

number = "1",

}

Nam, J, Villeneuve, E, Hensor, EMA, Conaghan, PG, Keen, H, Buch, MH, Gough, AKS, Green, MJ, Helliwell, PS, Keenan, AM, Morgan, AW, Quinn, MA, Reece, RJ, Van Der Heijde, DMFM, Wakefield, RJ & Emery, PD 2014, 'Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)', Annals of the Rheumatic Diseases, vol. 73, no. 1, pp. 75-85. https://doi.org/10.1136/annrheumdis-2013-203440

Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). / Nam, J.; Villeneuve, E.; Hensor, E.M.A. et al.
In: Annals of the Rheumatic Diseases, Vol. 73, No. 1, 2014, p. 75-85.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)

AU - Nam, J.

AU - Villeneuve, E.

AU - Hensor, E.M.A.

AU - Conaghan, P.G.

AU - Keen, Helen

AU - Buch, M.H.

AU - Gough, A.K.S.

AU - Green, M.J.

AU - Helliwell, P.S.

AU - Keenan, A.M.

AU - Morgan, A.W.

AU - Quinn, M.A.

AU - Reece, R.J.

AU - Van Der Heijde, D.M.F.M.

AU - Wakefield, R.J.

AU - Emery, P.D.

PY - 2014

Y1 - 2014

N2 - Objectives In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX and intravenous corticosteroid for remission induction. Methods In a 78-week multicentre randomised controlled trial, double-blinded to week 26, 112 treatment-naive RA patients (1987 American College of Rheumatology classification criteria) with disease activity score 44 (DAS44)>2.4 were randomised to MTX + IFX or MTX + single dose intravenous methylprednisolone 250 mg. A treat-to-target approach was used with treatment escalation if DAS44>2.4. In the IFX group, IFX was discontinued for sustained remission (DAS44

AB - Objectives In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX and intravenous corticosteroid for remission induction. Methods In a 78-week multicentre randomised controlled trial, double-blinded to week 26, 112 treatment-naive RA patients (1987 American College of Rheumatology classification criteria) with disease activity score 44 (DAS44)>2.4 were randomised to MTX + IFX or MTX + single dose intravenous methylprednisolone 250 mg. A treat-to-target approach was used with treatment escalation if DAS44>2.4. In the IFX group, IFX was discontinued for sustained remission (DAS44

U2 - 10.1136/annrheumdis-2013-203440

DO - 10.1136/annrheumdis-2013-203440

M3 - Article

SN - 0003-4967

VL - 73

SP - 75

EP - 85

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 1

ER -

Nam J, Villeneuve E, Hensor EMA, Conaghan PG, Keen H, Buch MH et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: A double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Annals of the Rheumatic Diseases. 2014;73(1):75-85. doi: 10.1136/annrheumdis-2013-203440